(I) in subparagraph (B)(ii)— 
(aa) in subclause (I), by 
striking ‘‘; and’’; 
(bb) in subclause (II), by 
striking the period at the end 
and inserting ‘‘; and’’; and 
(cc) by inserting at the end 
the following new subclause: 
‘‘(III) an analysis of the effects 
of trends of encounters of inadmis-
sible aliens at and between the ports 
of entry, and the effect of any in-
creases or changes in the level of 
trade and travel, on the capacity and 
ability of the Department of Home-
land Security to interdict and prevent 
the unlawful entry of illicit drugs into 
the United States by any means.’’; 
and 
(II) by adding at the end the fol-
lowing new subparagraph: 
‘‘(D) REQUIREMENT FOR CARIBBEAN BOR-
DER COUNTERNARCOTICS STRATEGY.— 
‘‘(i) PURPOSES.—The Caribbean Bor-
der Counternarcotics Strategy shall— 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(I) set forth the strategy of the 
Federal Government for preventing 
the illegal trafficking of drugs through 
the Caribbean region into the United 
States, including through ports of 
entry, between ports of entry, and 
across air and maritime approaches; 
‘‘(II) state the specific roles and 
responsibilities of each relevant Na-
tional Drug Control Program agency 
for implementing the strategy; 
‘‘(III) identify the specific re-
sources required to enable the relevant 
National Drug Control Program agen-
cies to implement the strategy, to the 
extent practicable; and 
‘‘(IV) be designed to promote, 
and not hinder, legitimate trade and 
travel. 
‘‘(ii) SPECIFIC CONTENT RELATED TO 
PUERTO RICO AND THE UNITED STATES 
VIRGIN ISLANDS.—The Caribbean Border 
Counternarcotics Strategy shall include— 
‘‘(I) a strategy to prevent the il-
legal trafficking of drugs to or 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
through Puerto Rico and the United 
States Virgin Islands, including meas-
ures to substantially reduce drug-re-
lated violent crime on such islands; 
and 
‘‘(II) recommendations for addi-
tional assistance or authorities, if any, 
needed by Federal, State, and local 
law enforcement agencies relating to 
the strategy, including an evaluation 
of Federal technical and financial as-
sistance, infrastructure capacity build-
ing, and interoperability deficiencies.’’; 
and 
(iv) in paragraph (5), by striking 
‘‘data’’ each place it appears and inserting 
‘‘evidence, data,’’; 
(B) in subsection (f)— 
(i) in paragraph (1), by striking ‘‘pub-
licly available in a machine-readable for-
mat’’ and inserting the following: ‘‘publicly 
available as an open Government data 
asset (as such term is defined in section 
3502 of title 44, United States Code)’’; 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
(ii) in paragraph (2), by inserting 
after ‘‘searchable format’’ the following: 
‘‘available for bulk download to the extent 
practicable’’; and 
(iii) by amending paragraph (3) to 
read as follows: 
‘‘(3) DATA.—The data included in the Drug 
Control Data Dashboard shall be updated annually 
with final data, and to the extent practicable, up-
dated quarterly with provisional data, that aligns 
with the goals of the performance measurement sys-
tem required under subsection (h) and include, at a 
minimum, the following: 
‘‘(A) For each substance identified by the 
Director as having a significant impact on illicit 
drug use in the United States, data sufficient 
to— 
‘‘(i) assess supply reduction efforts, 
including, to the extent practicable, the 
total amount of substances seized; 
‘‘(ii) assess drug use behaviors; 
‘‘(iii) estimate the prevalence of sub-
stance use disorders; 
‘‘(iv) show the number of fatal and 
non-fatal overdoses; and 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(v) assess the provision of substance 
use disorder treatment. 
‘‘(B) Any quantifiable measures the Direc-
tor determines to be appropriate to detail 
progress toward the achievement of the goals of 
the National Drug Control Strategy, including, 
to the extent practicable, data disaggregated by 
specific geographic areas or sub-populations of 
interest. 
‘‘(C) Data sufficient to assess the effective-
ness of such substance use disorder treatments. 
‘‘(D) To the extent practicable, data suffi-
cient to show the extent of prescription drug di-
version, trafficking, and misuse in the calendar 
year and each of the previous 3 calendar years. 
‘‘(E) Any quantifiable measures the Direc-
tor determines to be appropriate to detail 
progress toward the achievement of the goals of 
the National Drug Control Strategy, including 
to the extent practicable, data disaggregated by 
specific geographic areas or sub-populations of 
interest.’’; and 
(C) in subsection (g)(2)— 
(i) in subparagraph (D), by striking 
‘‘narcotics’’ and inserting ‘‘drugs’’; 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
(ii) in subparagraph (E), by striking 
‘‘drug use’’ and inserting ‘‘illegal drug 
use’’; and 
(iii) in subparagraph (F), by striking 
‘‘drug use’’ and inserting ‘‘illegal drug 
use’’; 
(6) in section 707 (21 U.S.C. 1706)— 
(A) in subsection (l)(2)(F), by inserting 
‘‘and authorities enforcing illicit drug traf-
ficking laws’’ after ‘‘task forces’’; 
(B) in subsection (m)(2), by inserting ‘‘, 
authorities enforcing illicit drug trafficking 
laws,’’ after ‘‘agencies’’; 
(C) in subsection (p)— 
(i) in paragraph (5). by striking ‘‘; 
and’’ and inserting a semicolon; 
(ii) in paragraph (6), by striking the 
period at the end and inserting ‘‘; and’’; 
and 
(iii) by inserting at the end the fol-
lowing new paragraph: 
‘‘(7) $298,579,000 for each of fiscal years 2025 
through 2031.’’; 
(D) in subsection (s)— 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
the Director may use amounts otherwise appro-
priated to carry out this section for such purpose. 
‘‘(u) ADDITIONAL JUDICIARY PROSECUTORIAL RE-
SOURCES.— 
‘‘(1) TEMPORARY
REASSIGNMENT
OF
ASSIST-
ANT UNITED STATES ATTORNEYS.— 
‘‘(A) AUTHORITY.—The Attorney General 
may identify assistant United States attorneys 
who may be made available for temporary reas-
signment under subsection (b)(2) for a period 
of time determined by the Attorney General in 
coordination with the Director, during which an 
assistant United States attorney shall prioritize 
the investigation and prosecution of organiza-
tions and individuals trafficking in fentanyl or 
fentanyl analogues. 
‘‘(B) EXTENSION
OF
REASSIGNMENT.— 
Such reassignment may be extended by the At-
torney General for such time as may be nec-
essary to conclude any ongoing investigation or 
prosecution in which the assistant United 
States attorney is engaged. 
‘‘(2) PROCESS
FOR
TEMPORARY
REASSIGN-
MENT.—The Attorney General may establish a proc-
ess under which the Director, in consultation with 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
the Executive Boards of each designated high inten-
sity drug trafficking area, may request such an as-
sistant United States attorney to be so temporarily 
reassigned. 
‘‘(v) USE OF FUNDS TO COMBAT FENTANYL TRAF-
FICKING.— 
‘‘(1) REQUIREMENT.—As part of the docu-
mentation that supports the President’s annual 
budget request for the Office, the Director shall sub-
mit to Congress a report describing the use of 
HIDTA funds for the purposes of enhancing 
fentanyl seizure and interdiction activities under 
subsection (s)(4) or (t) and to investigate and pros-
ecute organizations and individuals trafficking in 
fentanyl or fentanyl analogues in the prior calendar 
year. 
‘‘(2) CONTENTS.—The report shall include— 
‘‘(A) the amounts of fentanyl or fentanyl 
analogues seized by HIDTA-funded initiative in 
the area during the previous year; and 
‘‘(B) law enforcement intelligence and pre-
dictive data from the Drug Enforcement Ad-
ministration showing patterns and trends in 
abuse, 
trafficking, 
and 
transportation 
in 
fentanyl and fentanyl analogues. 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(w) REPORT ON DATA ANALYTICAL SERVICES PRO-
GRAM.— 
‘‘(1) REPORT.—With respect to the Data Ana-
lytical Services program (formally known as Hemi-
sphere), and any successor program, the Director 
shall submit to the Committee on Oversight and Ac-
countability and the Committee on the Judiciary of 
the House of Representatives, and the Committee on 
the Judiciary of the Senate a report every two years 
on any activities of the program— 
‘‘(A) funded by the Office; and 
‘‘(B) carried out in two years prior to the 
submission of the report. 
‘‘(2) CONTENTS OF REPORT.—The report re-
quired by paragraph (1) shall include the following: 
‘‘(A) A documentation of any activities of 
the Data Analytical Services program, includ-
ing— 
‘‘(i) the amount of searches conducted 
for each HIDTA; and 
‘‘(ii) each requesting local law enforce-
ment jurisdiction. 
‘‘(B) Information on how the program was 
funded and how funds were expended under the 
program, including information on any— 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(i) funding sources derived from 
each HIDTA’s funding allocation for a 
HIDTA, or any other source of funding, 
for the program; and 
‘‘(ii) payments made by the program 
to any non-governmental entity or external 
vendor. 
‘‘(C) A description of any policies and 
guidelines provided to HIDTA personnel and 
local law enforcement jurisdictions governing 
the operation of the program in order to ensure 
that such program does not infringe on rights 
protected under the Fourth Amendment or vio-
late legally protected privacy of United States 
citizens or individuals legally in the United 
States, along with any recommendations by the 
Director to strengthen such policies and guide-
lines.’’; 
(7) in section 709(f)(1) (21 U.S.C. 1708(f)(1)), 
by striking ‘‘shall’’ and inserting ‘‘may’’; 
(8) in section 709 (21 U.S.C. 1708)— 
(A) in subsection (f)(2)(B)(iii), by insert-
ing after ‘‘professionals’’ the following: ‘‘includ-
ing experts in evidence-based media campaigns, 
education, and evaluation’’; and 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
(B) in subsection (g), by striking ‘‘2023’’ 
and inserting ‘‘2031’’; 
(9) in section 711 (21 U.S.C. 1710), including 
the headings, by striking ‘‘Command and Control 
Plan’’ each place it appears and inserting ‘‘Strategic 
Plan’’; and 
(10) in section 714 (21 U.S.C. 1711), by insert-
ing before the period at the end the following: ‘‘and 
$20,000,000 for each of fiscal years 2025 through 
2031’’. 
(b) AMENDMENTS TO THE ANTI-DRUG ABUSE ACT 
OF 1988.—The Anti-Drug Abuse Act of 1988 (Public Law 
100–690) is amended— 
(1) in section 1024(a) (21 U.S.C. 1524(a)), by 
inserting before the period at the end the following: 
‘‘and $109,000,000 for each of fiscal years 2025 
through 2031’’; and 
(2) in section 1032(b) (21 U.S.C. 1532(b))— 
(A) by striking ‘‘$125,000’’ each place the 
term appears and inserting ‘‘$150,000’’; and 
(B) in paragraph (3)— 
(i) by striking subparagraph (A) and 
inserting the following: 
‘‘(A) IN
GENERAL.—Subject to subpara-
graph (F), the Administrator may award up to 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
2 additional grants under this paragraph to an 
eligible coalition awarded a grant under para-
graph (1) or (2) for any first fiscal year after 
the end of the 4-year or 9-year period following 
the period of the initial or subsequent grant 
under paragraph (1) or (2), as the case may 
be.’’; 
(ii) in subparagraph (B), by striking 
‘‘a renewal grant’’ and inserting ‘‘up to 2 
renewal grants’’; 
(iii) in subparagraph (C), by striking 
‘‘an additional grant’’ and inserting ‘‘the 
additional grants’’; and 
(iv) by striking subparagraph (D) and 
inserting the following: 
‘‘(D) RENEWAL GRANTS.—Subject to sub-
paragraph (F), the Administrator may award a 
renewal grant to a grant recipient under this 
paragraph for each fiscal year of the 4-fiscal- 
year period following the first fiscal year for 
which an additional grant under this paragraph 
is awarded in an amount not to exceed the 
amount of non-Federal funds raised by the coa-
lition, including in-kind contributions, for that 
fiscal year.’’. 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00025
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
(c) REAUTHORIZATION OF THE NATIONAL COMMU-
NITY ANTI-DRUG COALITION INSTITUTE.—Section 4(d) 
of Public Law 107–82 (21 U.S.C. 1521 note) is amended 
by striking ‘‘section 1032 of the National Narcotics Lead-
ership Act of 1988 (15 U.S.C. 1532), make a grant of 
$2 million under subsection (a), for each of the fiscal years 
2018 through 2023’’ and inserting ‘‘section 1024 of the 
National Narcotics Leadership Act of 1988 (21 U.S.C. 
1524), make a grant of $2,500,000 under subsection (a), 
for each of the fiscal years 2025 through 2031’’. 
(d) REAUTHORIZATION OF COMMUNITY-BASED COA-
LITION ENHANCEMENT GRANTS TO ADDRESS LOCAL 
DRUG CRISES.—Subsection (i) of section 103 of the Com-
prehensive Addiction and Recovery Act of 2016 (21 U.S.C. 
1536) is amended by inserting before the period at the 
end the following: ‘‘and $5,200,000 for each of fiscal years 
2025 through 2031’’. 
(e) REPORT REGARDING LIFE-SAVING OPIOID AN-
TAGONISTS OR REVERSAL AGENTS.—The Office of Na-
tional Drug Control Policy Reauthorization Act of 2006 
(Public Law 109–469) is amended by adding at the end 
the following new section: 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00026
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
‘‘SEC. 1121. REQUIREMENT FOR LIFE-SAVING OPIOID OVER-
DOSE REVERSAL STUDY. 
‘‘(a) FINDING.—Congress finds that it is vital to sup-
port access to treatment and emergency intervention tools 
to address drug addiction while also pursuing strategies 
to ensure communities have readily available access to life- 
saving drug overdose reversal medications, including 
opioid antagonists or reversal agents, such as naloxone, 
in case of an emergency. 
‘‘(b) REPORT.—Not later than 180 days after the 
date of the enactment of this section, the Director of the 
Office of National Drug Control Policy shall submit to 
Congress a report that contains the following: 
‘‘(1) A summary of the relevant roles, respon-
sibilities, and authorities of each relevant National 
Drug Control Program agency to ensure that life- 
saving drug overdose reversal medications are read-
ily available in case of an emergency, including life- 
saving opioid antagonists or reversal agents, such as 
naloxone, across the Nation. 
‘‘(2) A strategy for the Federal Government to 
ensure that State, local, and Tribal governments, 
and agencies thereof including law enforcement and 
public health and safety entities, have life-saving 
drug overdose reversal medications readily available 
in case of an emergency, including life-saving opioid 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00027
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
antagonists or reversal agents, such as naloxone, 
which at a minimum identifies— 
‘‘(A) any Federal and State policies and 
actions necessary for the relevant National 
Drug Control Program agencies to take to ad-
dress— 
‘‘(i) the challenges faced by phar-
macists, prescription drug providers, dis-
pensers (including manufacturers, distribu-
tors, and retailers), and other health care 
providers, to make such medications read-
ily available to patients over the counter 
for emergency use; 
‘‘(ii) the challenges faced by phar-
macists, health care providers, and State 
health officials to educate the public on the 
risks and benefits of such medications, in-
cluding how to effectively use such medica-
tions; and 
‘‘(iii) the appropriate training of State 
and local health care providers and first 
responders on the use of such medications; 
and 
‘‘(B) identifies any budgetary resources, 
personnel resources, licensing requirements, and 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00028
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
legal authorities that relevant National Drug 
Control Program agencies needs to enable the 
availability of such life-saving emergency drug 
overdose medications; 
‘‘(3) A summary of policies in effect before the 
submission of the report that are administered by— 
‘‘(A) the Director of the Office National 
Drug Control Policy; 
‘‘(B) the Secretary of Health and Human 
Services; and 
‘‘(C) each National Drug Control Program 
agency, as applicable. 
‘‘(4) A summary of the specific actions taken 
over the previous 10 years before the submission of 
the report by the Substance Abuse and Mental 
Health Services Administration and the Drug En-
forcement Administration to coordinate with one an-
other and with State health agencies to ensure 
that— 
‘‘(A) such treatments, including medica-
tions, are accessible to the public; and 
‘‘(B) appropriate public education on the 
use of, and the risks and benefits of, such treat-
ments, including medications, are readily avail-
able. 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00029
Fmt 6652
Sfmt 6201
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(c) UPDATES.—Any significant update made to the 
strategy included in the report required by paragraph 
(2)(B) after such report is submitted shall be included in 
the next National Drug Control Strategy submitted to 
Congress after such update is made.’’. 
Æ 
VerDate Sep 11 2014 
22:16 Sep 24, 2024
Jkt 049200
PO 00000
Frm 00030
Fmt 6652
Sfmt 6301
E:\BILLS\H9598.IH
H9598
ssavage on LAPJG3WLY3PROD with BILLS